- Stocks
- Pharma & Healthcare
- Sandu Pharma
Sandu Pharma share price
NSE: SANDUPHQPharma & HealthcareDrug Manufacturers - Specialty & Generic
Sandu Pharma at a glance
With a market capitalisation of ₹41 Cr, it ranks 3189th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 3.7% in FY25. In Q4 FY25, the quarter ended 31 Mar 2025, revenue was ₹14 Cr (−9.8% year on year) and net profit ₹0 Cr (−44.1%), on a consolidated basis. Promoters held 37.79% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹41 CrRank 3189 on NSE
- Price to book
- 1.13×FY25
- EPS (TTM)
- ₹3.04to Q4 FY25
- ROE
- 3.7%FY25
- ROCE
- 5.2%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 2.3%FY25
- Book value / share
- ₹43.49FY25
- Dividend payout
- 49.8%FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Sandu Pharma quarterly results
| Quarter | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹18 Cr | ₹17 Cr | ₹17 Cr | ₹16 Cr | ₹17 Cr | ₹18 Cr | ₹18 Cr | ₹14 Cr |
| Revenue YoY | — | — | +2.0% | +2.2% | −3.5% | +6.6% | +5.4% | −9.8% |
| Net profit | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr |
| Net profit YoY | — | — | −56.3% | +118.5% | +54.5% | −9.1% | +166.7% | −44.1% |
| Net margin | 0.6% | 3.3% | 1.2% | 3.8% | 1.0% | 2.8% | 3.0% | 2.3% |
| EPS | ₹0.11 | ₹0.57 | ₹0.21 | ₹0.62 | ₹0.17 | ₹1.95 | ₹0.58 | ₹0.34 |
Sandu Pharma financials
| Item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | ₹65 Cr | ₹67 Cr | ₹67 Cr |
| Operating profit | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Net profit | ₹2 Cr | ₹1 Cr | ₹2 Cr |
| EPS (₹) | ₹2.00 | ₹2.00 | ₹2.00 |
| Cash from operations | ₹0 Cr | ₹1 Cr | ₹1 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹39 Cr | ₹41 Cr | ₹42 Cr |
Sandu Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 42.90% | 42.90% | 42.90% | 37.79% | 37.79% | 37.79% |
| Domestic institutions | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Non-institutions | 57.09% | 57.09% | 57.09% | 62.21% | 62.21% | 62.21% |
Sandu Pharma vs peers
The listed Pharma & Healthcare companies nearest to Sandu Pharma by market capitalisation.
Ask anything about Sandu Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against SANDUPHQ's own history. Try: “Why has SANDUPHQ moved over the last three months?” · “Backtest a 50-day moving-average crossover on SANDUPHQ over five years” · “Compare SANDUPHQ with AMKAY on margins and valuation”
Frequently asked questions about Sandu Pharma
What is the market cap of Sandu Pharma?
Sandu Pharma's market capitalisation is ₹41 Cr (₹41 Cr) at the 22 Oct 2026 close, ranking 3189th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Sandu Pharma?
Return on equity was 3.7% in FY25 and return on capital employed was 5.2% in FY25 (consolidated figures).
Is Sandu Pharma a debt-free company?
Sandu Pharma is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Sandu Pharma's latest quarterly results?
For Q4 FY25 (quarter ended 31 Mar 2025), Sandu Pharma reported revenue of ₹14 Cr, −9.8% year on year, and net profit of ₹0 Cr, −44.1% year on year.
What is the shareholding pattern of Sandu Pharma?
As of 30 Jun 2026: promoters 37.79%, domestic institutions 0.01%, non-institutions 62.21%.
Who are Sandu Pharma's competitors?
The listed Pharma & Healthcare companies closest to Sandu Pharma by market cap are Amkay Products, Shelter Pharma, Vista Pharma, KMS Medisurgi, Medicamen Organ and Roopa Ind.
Is Sandu Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Sandu Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SANDUPHQ against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text